Relugolix: New 0ral Gonadotropin-Releasing Hormone (GnRH) Antagonist
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2019, Vol 18, Issue 3
Abstract
With the recent development of Gonadotropin-Releasing Hormone (GnRH) analogs, physicians have manipulated gonadotropin secretion and, consequently, to treat sex steroid-dependent hormonal disorders such as central precocious puberty in children, and benign prostatic hypertrophy and prostate cancer in men, and endometriosis, leiomyoma and breast cancer in women. GnRH agonists can cause transient deterioration of clinical symptoms associated with an initial surge of gonadotropins and gonadal hormones. However, the peptide antagonists must be administered by frequent subcutaneous injection or sustained release formulation due to orally fragile bioavailability. A new oral nonpeptide GnRH antagonist, relugolix, promptly lowers pituitary gonadotropin by GnRH receptor competition lowering estrogen level in women and testosterone in men within a few days without the symptom flare-up observed with GnRH agonist. Sex steroid levels to baseline and menses resumed more quickly after the oral GnRH antagonist withdrawal. The oral GnRH antagonist may play an ideal role in therapeutic management of the estrogen or androgen-dependent disorders.The decapeptide hormone, Gonadotropin-Releasing Hormone (GnRH), induces gonadotropins (luteinizing hormone and folliclestimulating hormone) secretion from the anterior pituitary in an orderly way which is important for the control of gonadal function and normal ovarian cyclicity. The action of GnRH is mediated by its binding to high affinity membrane receptors belonging to the seven-transmembrane receptor family. It is noted that sustained occupancy of the receptor with GnRH itself or a GnRH agonist caused desensitization. The GnRH agonist-induced downregulation has been applied to manipulate gonadotropin secretion and, consequently, to treat sex steroid (estrogen or androgen)- dependent hormonal disorders such as central precocious puberty in children, and benign prostatic hypertrophy and prostate cancer in men, and endometriosis, leiomyoma and breast cancer in women [1-4]. However, GnRH agonists can cause transient worse clinical symptoms associated with an initial surge of gonadotropins and gonadal hormones [1-4]. GnRH antagonists, in contrast to GnRH agonists, achieve an immediate reduction of theses hormones and thus fast onset of therapeutic effects without undesirable adverse events induced by the flare-up. To data, several peptide GnRH antagonists have been developed, including cetrorelix [5,6] and ganirelix for in vitro fertilization [7,8], and degarelix for advanced prostate cancer [9,10]. These peptide antagonists, however, had to be administered by frequent subcutaneous injection or sustained release formulation due to orally fragile bioavailability.Many nonpeptide GnRH antagonists have been developed by several research groups. Relugolix (Relumina®), an oral nonpeptide GnRH receptor antagonist, promptly suppresses pituitary gonadotropin by GnRH receptor competition, lowering sex steroids levels within a few days, without the symptom flareup associated with GnRH agonist [11-13]. More recently, Osuga et al. [14] demonstrated the noninferiority of relugolix compared with current GnRH analogs in reducing heavy menstrual bleeding associated with uterine leiomyoma. This novel oral GnRH antagonist showed a rapid effect on the symptoms and reduced the leiomyoma and uterine volumes. Depot preparation of GnRH agonists also reduce leiomyoma size but have a delayed onset and must be given by monthly injection. Once daily oral intake achieved a similar proportion of heavy menstrual bleeding responders at 6-12 weeks.
Authors and Affiliations
Atsushi Imai, Hazuki Kagawa, Satoshi Ichigo, Hiroshi Takagi, Kazutoshi Matsunami, Masashi Hori
Keywords
Related Articles
- EP ID EP630516
- DOI 10.26717/BJSTR.2019.18.003169
- Views 151
- Downloads 0
Vitiligo Definition Classification Treatment and Prognosis A Personal Opinion
Vitiligo has no respect for race, socioeconomic status or age. The following are celebrities who have or have had Vitiligo. Michael Jackson, Lee Thomas Americo Garcia Holly Marie Combs, Winnie Harlow, Rasheed Wallace, Ta...
Opinions and Controversies in Problem of The So-Called Idiopathic Scoliosis. Information About Etiology, New Classification and New Therapy
The biomechanical etiology of the so-called idiopathic scoliosis [adolescent idiopathic scoliosis (AIS)] was the subject of the author’s research from 1984 to 2009 in the Pediatric Orthopedic and Rehabilitation Departmen...
Preliminary Blood Compatibility Comparison of Silk Fibroin Dissolved by different Solvents
Silk fibroin possesses good cytocompatibility and biodegradability, was a potential material for wound haemostasis. Ca2+ act as a coagulation factor in cascade pathway for thrombin generation, it can be chelated to silk...
Screening of Oropharyngeal Dysphagia in Patients with Diabetes Mellitus
Background: Diabetes mellitus is a systemic endocrinal disease that results either from deficiency of insulin hormone (type 1) or from insulin resistance or both (type 2). Literature is scarce related to dysphagia with d...
The Consideration of the Human to Protect against Cybercriminals
For years, cybercrime has been secured by antimalware software and digital services, mainly involving engineers with various professional skills in the fields of IT and digital technology. Thus, the company, the administ...